Skip to main content Accessibility help
×
Home

Thrombolysis for acute ischemic stroke: does it work?—the con position

  • Chris Johnstone (a1) (a2)
  • Please note a correction has been issued for this article.
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Thrombolysis for acute ischemic stroke: does it work?—the con position
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Thrombolysis for acute ischemic stroke: does it work?—the con position
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Thrombolysis for acute ischemic stroke: does it work?—the con position
      Available formats
      ×

Abstract

Copyright

Corresponding author

Correspondence to: Dr. Chris Johnstone, Emergency Department, Caboolture Hospital, LMB 3, Caboolture, Qld 4510, Australia. Email: chrisjohnstone7@westnet.com.au

References

Hide All
1. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet 1994;343(8893):311-322.
2. Wardlaw, JM, Murray, V, Berge, E, Del Zoppo, GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2014;29(7):CD000213. doi:10.1002/14651858.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-1587.
4. Hacke, W, Kaste, M, Bluhmki, E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-1329.
5. Eissa, A KI, Levi, C, Sturm, J, et al. Understanding the reasons behind the low utilisation of thrombolysis in stroke. Australas Med J 2013;6(3):152-167.
6. Fatovich, DM. Believing is seeing: stroke thrombolysis remains unproven after the third international stroke trial (IST-3). Emerg Med Australas 2012;24(5):477-479.
7. Hoffman, JR, Schriger, DL. A graphic reanalysis of the NINDS trial. Ann Emerg Med 2009;54(3):329-336.e35.
8. Ingall, TJ, O’Fallon, WM, Asplund, K, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004;35(10):2418-2424.
9. Middleton, S, Levi, C, Ward, J, et al. Death, dependency and health status 90 days following hospital admission for acute stroke in NSW. Int Med J 2011;41(10):736-743.
10. Wardlaw, JM, Murray, V, Berge, E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012;379(9834):2364-2372.
11. Hacke, W, Furlan, AJ, Al-Rawi, Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8(2):141-150.
12. Furlan, AJ, Eyding, D, Albers, GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37(5):1227-1231.
13. Hacke, W, Albers, G, Al-Rawi, Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36(1):66-73.
14. Konstantinides, S, Goldhaber, SZ. Pulmonary embolism: risk assessment and management. Eur Heart J 2012;33(24):3014-3022.
15. Hacke, W, Donnan, G, Fieschi, C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363(9411):768-774.
16. Group, ISTc, Sandercock, P, Wardlaw, JM, Lindley, RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 2012;379(9834):2352-2363.
17. Leyden, JM, Chong, WK, Kleinig, T, et al. A population-based study of thrombolysis for acute stroke in South Australia. Med J Aust 2011;194(3):111-115.
18. Wahlgren, N, Ahmed, N, Davalos, A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. [Erratum appears in Lancet 2007;369(9564):826]. Lancet 2007;369(9558):275-282.
19. Albers, GW, Bates, VE, Clark, WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283(9):1145-1150.
20. Hill, MD, Buchan, AM. Canadian Alteplase for Stroke Effectiveness Study I. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172(10):1307-1312.
21. Katzan, IL, Furlan, AJ, Lloyd, LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283(9):1151-1158.
22. Katzan, IL, Hammer, MD, Furlan, AJ, et al. Cleveland Clinic Health System Stroke Quality Improvement T. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003;34(3):799-800.
23. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group. Lancet 1995;346(8989):1509-1514.
24. Hacke, W, Kaste, M, Fieschi, C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274(13):1017-1025.
25. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicentre Acute Stroke Trial--Europe Study Group. N Engl J Med 1996;335(3):145-150.
26. Donnan, GA, Davis, SM, Chambers, BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996;276(12):961-966.
27. Hacke, W, Kaste, M, Fieschi, C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352(9136):1245-1251.
28. Clark, WM, Wissman, S, Albers, GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282(21):2019-2026.
29. Clark, WM, Albers, GW, Madden, KP, Hamilton, S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 2000;31(4):811-816.

Keywords

Type Description Title
WORD
Supplementary materials

Johnstone Supplementary Material
Johnstone Supplementary Material

 Word (72 KB)
72 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

A correction has been issued for this article: